As HER family members are involved in pancreatic carcinoma and are activated through dimerization, we tested the combination of cetuximab (anti-EGFR/HER1) and trastuzumab (anti-HER2 antibody). The gene discussed is EGFR; the disease is exocrine pancreatic carcinoma.